|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Gilead Sciences Going Down When It Should Go Up [Seeking Alpha, 12/8/2017]
Gilead Sciences Q1 2016 Key Insights [May 3, 2016 at Seeking Alpha]
Wider Reach Is Sought for Costly New Hepatitis C Treatments [Aug. 25, 2015, New York Times]
Earlier articles are below the summaries table.
William P. Meyers Analyst Conference summaries available:
2018 |
|||
 |
|
|
|
May 1, 2018 |
July 25, 2018 |
Oct. 25, 2018 |
Feb. 04, 2019 |
Q1 2018 |
Q2 2018 |
Q3 2018 |
Q4 2018 |
2017 |
|||
|
|
|
|
May 2, 2017 |
July 26, 2017 |
Oct. 26, 2017 |
February 6, 2018 |
Q1 2017 |
Q2 2017 |
Q3 2017 |
Q4 2017 |
2016 |
|||
|
|
|
|
04/28/2016 |
07/25/2016 |
11/01/2016 |
02/07/2016 |
Q1 2016 |
Q2 2016 |
Q3 2016 |
Q4 2016 |
2015 |
|||
|
|
|
|
04/30/2015 |
07/28/2015 |
10/27/2015 |
02/02/2016 |
Q1 2015 |
Q2 2015 |
Q3 2015 |
Q4 2015 |
2014 |
|||
|
|
|
|
04/22/2014 |
07/23/2014 |
10/28/2014 |
02/03/2015 |
Q1 2014 |
Q2 2014 |
Q3 2014 |
Q4 2014 |
2013 |
|||
|
|
|
|
05/02/2013 |
07/25/2013 |
10/29/2013 |
02/04/2014 |
Q1 2013 |
Q2 2013 |
Q3 2013 |
Q4 2013 |
2012 |
|||
|
|
|
|
04/26/2012 |
07/26/2012 |
10/23/2012 |
02/04/2013 |
Q1 2012 |
Q2 2012 |
Q3 2012 |
Q4 2012 |
2011 |
|||
|
|
|
|
04/20/2011 |
07/26/2011 |
10/27/2011 |
02/02/2012 |
Q1 2011 |
Q2 2011 |
Q3 2011 |
Q4 2011 |
2010 |
|||
|
|
|
|
4/20/2010 |
07/20/2010 |
10/19/2010 |
01/25/2011 |
Q1 2010 |
Q2 2010 |
Q3 2010 |
Q4 2010 |
2009 |
|||
|
|
|
|
04/21/2009 |
07/21/2009 |
10/20/2009 |
01/26/2010 |
Q1 2009 |
Q2 2009 |
Q3 2009 |
Q4 2009 |
2008 |
|||
|
|
|
|
04/16/2008 |
07/17/2008 |
10/16/2008 |
01/27/2009 |
Q1 2008 |
Q2 2008 |
Q3 2008 |
Q4 2008 |
2007 |
|||
|
|
|
|
01/23/2008 |
10/18/2007 |
7/19/2007 |
4/18/2007 |
Q4 2007 |
Q3 2007 |
Q2 2007 |
Q1 2007 |
Gilead Sciences: P/E and Pipeline Beyond HCV [June 9, 2015 at Seeking Alpha]
Could GlaxoSmithKline Be a Better Investment Than Gilead? [September 17, 2014 at Seeking Alpha]
The Solid Gold Wonder Drug [September 2014 Scientific American]
Gilead Down on Merck-Idenix Deal, But Little to Fear [June 9, 2014 at Seeking Alpha]
FDA Approves Zydelig (idelalisib) for CLL, FL, and SLL [July 23, 2014 Gilead press release]
Gilead Sciences Hepatitis C Approval May Be Factored In [July 30, 2013]
Gilead Sciences Pipeline Remains Undervalued [December 3, 2012]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Gilead Sciences Looks for Hepatitis C Cure [April 29, 2012]
Gilead Sciences Readies Pipeline [July 27, 2011]
Gilead Sciences, Antivirals, and Tamiflu [January 26, 2011]
Gilead Sciences Rebuilds Pipeline Optimism [October 24, 2010]
Gilead Sciences (GILD) Q2 Outlook [July 6, 2009]
Gilead (GILD) Thrives Despite Downturn [October 21, 2008]
Aztreonam Lysine Rejected by FDA [September 20, 2008]
Gilead Should Rise on Penetration, Viread [September 10, 2008]
Gilead Preps for Atripla in Europe [January 24, 2008]
Choosing a Biotech Stock 2: Gilead [September 10, 2007]
Gilead is a biotechnology pharmaceutical company; products include Atripla, Truvada, and Sovaldi. So far it has specialized in anti-viral agents for HIV, Hepatitis B, and Hepatitis C as well as cancer and cardiovascular therapies.
Gilead Sciences Web site:
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but its possible. Before making or terminating an investment you should always verify any factual basis of your decision.